Arbutus Biopharma (ABUS) Misses Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to Arbutus Biopharma (ABUS) Misses Q2 EPS by 1c

Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 7, 2020 7:31 AM EDT

Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020

AB-836, an oral capsid inhibitor, remains on track for completion of IND enabling studies by the end of 2020

Actively screening multiple new molecular entities in recently initiated COVID-19 research program

Cash runway guidance extended into mid-2022

Conference Call and Webcast Scheduled Today at 8:45 AM ET

... More